Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma.

Marit, Gérald; Fabères, C; Pico, J. L.; Boiron, Jean‐Michel; Bourhis, J. H.; Brault, P; Bernard, P; Foures, C; Cony‐Makhoul, Pascale; Puntous, M.; Vezon, G; Broustet, A; Girault, D; Reiffers, Josy

doi:10.1200/jco.1996.14.4.1306

Cited by 26 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evaluating all MM stages (I to III) aged < 66 years (Table 5), the 4-year survival is 46% in our series and 40% (32-63%) in five Attal et al (1996);Marit et al (1996). bPresent series; Attal et al (1996).…”

Section: Discussionmentioning

confidence: 77%

“…The tables are compiled using median and 4-year survival, as the commonest data can be found in most BMT series (Fermand et al, 1993;Jagannath et al, 1993;Bjorkstrand et al, 1994;Cunningham et al, 1994;Harosseau et al, 1995;Attal et al, 1996;Bensiger et al, 1996;Marit et al, 1996;Vesole et al, 1996) and are useful for comparison with our series (Table 3). Additionally, for literature series, data on 4-year survival given by the authors (as a % of single series) have also been cumulated by calculating the actual percentage of patients of all series surviving 4 years.…”

Section: Discussionmentioning

confidence: 99%

“…The relevance of age tends to be lower when this parameter is included as a continuous variable into multiple regression analysis (Grignani et al, 1995). The actual more relevant prognostic role for relatively young age in MM is that it is a prerequisite for administering allogeneic or autologous bone marrow transplantation (BMT) (Fermand et al, 1993;Jagannath et al, 1993;Bjorkstrand et al, 1994;Cunningham et al, 1994;Gharton et al, 1995;Harosseau et al, 1995Harosseau et al, , 1996Attal et al, 1996;Bensiger et al, 1996;Marit et al, 1996;Vesole et al, 1996).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol

et al. 1998

View full text Add to dashboard Cite

Summary Age could influence the prognosis of multiple myeloma patients treated with conventional chemotherapy. Between January 1987 and March 1990, 341 consecutive previously untreated patients with multiple myeloma received chemotherapy within the prospective, multicentre, randomized Protocol MM87. Survival was evaluated in patients aged > or < 66 years (the median age for the whole series) and in a subgroup of patients aged < 55 years. These groups were similar for main clinical characteristics, including results of cytostatic treatment. As of May 1996, 271 (79%) of the 341 patients had died, and median follow-up of the 70 (21%) living patients was 82 months. Overall, younger patients survived longer than older ones. In fact, in patients > and < 66 years, median survival was 31 and 44 months (P < 0.00095) and the percentage of patients surviving over 72 months was 17% and 32% (P = 0.0018) respectively; in patients < 55 years, these figures were 57 months and 35% respectively (P = 0.02 and 0.01, with respect to patients aged . 55 years). In all groups, about 50% of the patients surviving over 72 months had stage I disease. For multiple myeloma patients treated with chemotherapy, survival is favourably affected by relatively young age and early stage of disease.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol

et al. 1998

View full text Add to dashboard Cite

show abstract

“…13 All the patients had aggressive MM defined as: (1) stage II or III MM at diagnosis according to the Durie-Salmon staging; 14 (2) plasmocytoma or stage I MM with no response to treatment or relapse after a previous response to treatment; and (3) plasma cell leukemia. The patients were eligible for HDCYC if they had aggressive MM, no history of cyclophosphamide-induced cystitis, plasma creatinine levels of less than 150 mol/l and normal hepatic and cardiac function.…”

Section: Patientsmentioning

confidence: 99%

“…1 Patients with high-risk multiple myeloma (MM) seem to benefit particularly from this type of treatment. [2][3][4][5] Moreover, in patients under the age of 65 with aggressive MM, the results of a recent randomized trial of the Intergroupe Francais du Myelome have shown the superiority of autologous transplantation over conventional treatment. 6 During the past few years, peripheral blood progenitor cells (PBPC) have progressively replaced bone marrow (BM) cells as the source of stem cells to rescue hematopoiesis after myeloablative treatment.…”

Section: Introductionmentioning

confidence: 99%

Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study

et al. 1998

Self Cite

View full text Add to dashboard Cite

The aim of the study was to analyze the factors influencing peripheral blood progenitor cell (PBPC) collection after high-dose cyclophosphamide (HDCYC) (7 g/m 2 ) and hematopoietic recovery after autologous transplantation of HDCYC-mobilized PBPC (ABPCT) in 116 patients with aggressive multiple myeloma (MM). Following HDCYC 74 patients received hematopoietic growth factors (HGF), either G-CSF (n = 19) or GM-CSF (n = 55). All the patients were subsequently planned to undergo ABPCT. PBPC collection was possible for 106 patients. The most important prognostic factor for collection of more than 25 × 10 4 CFU-GM cells/kg and 2 × 10 6 CD34 + cells/kg was the use of HGF (P = 0.002 and 0.009, respectively). Previous use of an alkylating agent, response to treatment before HDCYC, and interval between diagnosis and HDCYC were also significant factors (P = 0.004, 0.025 and 0.001, respectively). The number of CFU-GM cells infused was the most important parameter for rapid and complete hematological recovery after ABPCT (P Ͻ 0.0001). Thus the use of HGF post-HDCYC is the major factor which, associated with reduced time between diagnosis and HDCYC and the use of an alkylating agent, could increase the numbers of hematopoietic progenitors collected, and subsequently improve hematopoietic recovery following ABPCT in MM patients.

show abstract

Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters

et al. 2006

View full text Add to dashboard Cite

We studied the prognostic value of parameters of angiogenesis on bone marrow biopsies in newly diagnosed multiple myeloma (MM) patients. Angiogenesis parameters studied were the microvessel count done manually on light microscopy (MVD-A), microvessel count done by using computerized image analyzer (MVD-B), and total vascular area (TVA) measured by computerized image analyzer. One hundred ten newly diagnosed cases of MM treated at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, were analyzed with respect to clinical features, laboratory findings, histological features, angiogenesis parameters, and responses to the treatment on follow-up. Twenty age-and sex-matched controls were studied for comparing with angiogenesis of the test cases. Bone marrow microvessels were examined using immunohistochemical staining for CD34. MVD-A (range 4.9-85.2; mean 28.2; SD 19.4), MVD-B (range 2.0-26.9; mean 11.7; SD 5.9), and TVA measured in percentage (range 0.1-17.1; mean 2.4; SD 2.5) were measured for test cases (n = 110). Grading of angiogenesis parameters of the test cases were done; such that angiogenesis parameters of controls (taken as baseline) were grade I. There was a statistically highly significant correlation between (MVD-A vs MVD-B, pcc = 0.92; MVD-A vs TVA, pcc = 0.78; MVD-B vs TVA, pcc = 0.76). The myeloma cases had significantly higher angiogenesis parameters when compared with controls (Kruskall-Wallis test, P < 0.001). ''Complete responders'' (n = 38/110) had significant lower angiogenesis (Mann-Whitney U test, P < 0.001) than ''nonresponders'' (n = 72/110). On treatment follow-up ''rapid disease progressors'' had the highest levels of angiogenesis (mean rank for MVD-A = 84.7, MVD-B = 82.1, and TVA = 81.1). On multivariate (logistic regression) analysis, factors found to have independent prognostic significance in complete responders (adjusted odd ratio (95% CI,

show abstract

Autologous peripheral-blood progenitor-cell support following high-dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma.

Abstract: High-dose chemotherapy or chemoradiotherapy followed by autologous PBPC support in MM is feasible and efficient. Further studies are needed to confirm these encouraging, although preliminary, results and to compare this technique with other therapeutic strategies.

Cited by 26 publications

References 20 publications

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol

Relevance of age on survival of 341 patients with multiple myeloma treated with conventional chemotherapy: updated results of the MM87 prospective randomized protocol

Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study

Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters

Contact Info

Product

Resources

About